PAVmed (NASDAQ:PAVM) Upgraded to Strong-Buy at Zacks Research

PAVmed (NASDAQ:PAVM) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d)” rating on shares of PAVmed in a research report on Wednesday. Ascendiant Capital Markets boosted their price objective on PAVmed from $19.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, PAVmed has a consensus rating of “Moderate Buy” and an average price target of $20.00.

PAVmed Stock Performance

Shares of PAVM stock opened at $0.49 on Thursday. PAVmed has a fifty-two week low of $0.30 and a fifty-two week high of $1.25. The stock has a 50 day moving average price of $0.45 and a two-hundred day moving average price of $0.58. The company has a market capitalization of $10.71 million, a P/E ratio of 0.42 and a beta of 1.07.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC increased its position in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the period. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. Institutional investors own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.